Ligand enters into global OmniAb license agreement with Pandion
Ligand announces it has entered into a worldwide OmniAb license agreement with Pandion Therapeutics. Under the agreement, Pandion will be able to use Ligand's full OmniAb antibody discovery platform which includes OmniRat, OmniFlic, OmniMouse, OmniChicken and OmniClic. OmniAb is licensed to over 40 corporate partners globally, and this deal with Pandion adds to a growing portfolio of OmniAb discovery and clinical development programs. Pandion will pay Ligand an up-front platform access fee, development and regulatory milestone payments, and potential royalties on sales of marketed products. "This agreement provides Pandion access to the industry's only human immunoglobulin transgenic rats and chickens for efficient generation of mono- and bispecific antibody therapeutics," said John Higgins, CEO of Ligand.